IRIS
CESARO, ARTURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.007
AS - Asia 2.487
NA - Nord America 1.572
SA - Sud America 470
AF - Africa 41
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 10.580
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 4.730
US - Stati Uniti d'America 1.526
SG - Singapore 915
CN - Cina 590
IE - Irlanda 484
HK - Hong Kong 401
BR - Brasile 387
IT - Italia 297
VN - Vietnam 193
DE - Germania 146
KR - Corea 144
GB - Regno Unito 120
IN - India 96
AR - Argentina 41
FR - Francia 36
AT - Austria 29
GR - Grecia 25
MX - Messico 23
UA - Ucraina 23
BD - Bangladesh 22
FI - Finlandia 22
SE - Svezia 22
TR - Turchia 20
JP - Giappone 19
ID - Indonesia 17
BE - Belgio 16
CA - Canada 15
NL - Olanda 15
IQ - Iraq 13
EG - Egitto 11
CO - Colombia 10
EC - Ecuador 10
PK - Pakistan 10
ZA - Sudafrica 10
ES - Italia 8
MA - Marocco 8
LT - Lituania 7
PL - Polonia 7
VE - Venezuela 7
IR - Iran 5
TH - Thailandia 5
UZ - Uzbekistan 5
CL - Cile 4
KZ - Kazakistan 4
PA - Panama 4
SA - Arabia Saudita 4
TN - Tunisia 4
UY - Uruguay 4
AZ - Azerbaigian 3
DK - Danimarca 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
NP - Nepal 3
PE - Perù 3
PY - Paraguay 3
TW - Taiwan 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
EU - Europa 2
JO - Giordania 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
AU - Australia 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CH - Svizzera 1
CR - Costa Rica 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
GH - Ghana 1
HR - Croazia 1
IS - Islanda 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
RO - Romania 1
SY - Repubblica araba siriana 1
Totale 10.580
Salva come PNG Salva come JPEG
Città #
Moscow 1.693
Dublin 475
Hong Kong 401
Santa Clara 356
Singapore 349
Chandler 237
Hefei 170
Seoul 143
New York 102
Ashburn 91
The Dalles 77
Naples 71
Beijing 68
Bengaluru 68
Ho Chi Minh City 68
Princeton 51
Roxbury 51
Hanoi 37
Jacksonville 37
Bremen 34
Nuremberg 33
Cambridge 30
Los Angeles 25
São Paulo 24
Dallas 23
Medford 23
Des Moines 22
Falkenstein 21
Munich 19
Milan 17
Boardman 16
Brussels 16
Aversa 14
Rio de Janeiro 14
Da Nang 13
Mexico City 13
Ann Arbor 12
Helsinki 12
Guangzhou 11
Hyderabad 11
Vienna 11
Wilmington 11
Nanjing 10
Belo Horizonte 8
Campinas 8
Curitiba 8
Ercolano 8
Sivas 8
Amsterdam 7
Cairo 7
Caserta 7
Dhaka 7
Frankfurt am Main 7
Haiphong 7
Jinan 7
London 7
Rome 7
Baghdad 6
Brasília 6
Salerno 6
Tokyo 6
Turin 6
Bangkok 5
Bologna 5
Columbus 5
Council Bluffs 5
Hải Dương 5
Islamabad 5
Jakarta 5
Johannesburg 5
Lappeenranta 5
Ninh Bình 5
Osasco 5
Porto Alegre 5
San Francisco 5
Stockholm 5
Thái Bình 5
Toronto 5
Boston 4
Bresso 4
Brooklyn 4
Buenos Aires 4
Campo Grande 4
Caraglio 4
Chicago 4
Florence 4
Guarulhos 4
Guayaquil 4
Houston 4
Istanbul 4
Montreal 4
Porto Velho 4
Salvador 4
San Jose 4
Shenyang 4
Tashkent 4
Turku 4
Vicenza 4
Warsaw 4
Woodbridge 4
Totale 5.281
Salva come PNG Salva come JPEG
Nome #
Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients: an Italian single-center experience 156
Advanced Heart Failure in Special Population—Pediatric Age 153
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry 145
Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease 144
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy 142
Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition 137
Diagnosis and Management of Cardiovascular Involvement in Fabry Disease 137
Childhood obesity: An overview of laboratory medicine, exercise and microbiome 136
Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience 130
New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia 130
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry 118
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 117
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approach 116
Antithrombotic therapy in patients with atrial high-rate episodes (AHREs): Current evidence and open questions 115
Antithrombotic Therapy Optimization in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention 115
Alcohol Septal Ablation in Patients with Hypertrophic Obstructive Cardiomyopathy: A Contemporary Perspective 113
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry) 113
Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry 113
Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease 111
Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge 111
The Role of Genetic Testing in Patients with Heritable Thoracic Aortic Diseases 110
How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study 106
Antithrombotic Therapy after TAVI: Evidence, Discordance, and Clinical Implications 104
New frontiers in antiplatelet therapy: guided therapy and de-escalation after acute coronary syndrome or percutaneous coronary intervention 103
Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go 103
SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes 103
Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future? 102
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 100
Early-onset MINOCA: Prognostic implications and considerations for practice 100
GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes 100
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine 100
Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque 99
Multimodality Imaging in Arrhythmogenic Left Ventricular Cardiomyopathy 99
Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement 98
Discrepancies Between Physician-Perceived and Calculated Cardiovascular Risk in Primary Prevention: Implications for LDL-C Target Achievement and Appropriate Lipid-Lowering Therapy 97
Role of LipoprotEin(a) in CardiovascuLar diseases and premature acute coronary syndromes (RELACS study): Impact of Lipoprotein(a) levels on the premature coronary event and the severity of coronary artery disease 97
Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry 97
Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent 97
ICARUS score for predicting peri-procedural bleeding in patients undergoing percutaneous coronary intervention with cangrelor 96
Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice 96
Dietary thiols: A potential supporting strategy against oxidative stress in heart failure and muscular damage during sports activity 96
Long-Term Antithrombotic Therapy in Patients with Atrial Fibrillation and Percutaneous Coronary Intervention 95
Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence 95
Improving adherence to Ticagrelor in patients after acute coronary syndrome: Results from the PROGRESS trial 94
Coronary stent thickness: thinner is (always) better for all lesions? 94
[Long COVID: nosographic aspects and clinical epidemiology] 93
null 93
Circulating culprit or therapeutic bullseye: lipoprotein(a) in cardiovascular risk assessment and novel therapeutic prospects 93
Visceral adipose tissue and residual cardiovascular risk: a pathological link and new therapeutic options 92
The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review 92
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study 92
Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies 91
SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction 91
The Biological Role of Vitamins in Athletes’ Muscle, Heart and Microbiota 91
Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis 90
Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: A single country, multicenter, observational study (AT-TARGET-IT) 90
Ticagrelor monotherapy after acute coronary syndrome: lessons from the ULTIMATE-DAPT trial 88
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry 87
The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy 87
Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis? 87
Use of bempedoic acid for LDL cholesterol lowering and cardiovascular risk reduction: a consensus document from the Italian study group on atherosclerosis, thrombosis and vascular biology 86
Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta regression analysis of randomized controlled trials 85
Ipercolesterolemia e referti di laboratorio: documento congiunto della Società Italiana di Cardiologia (SIC) e Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica - Medicina di Laboratorio (SIBioC) 84
The Impact of Physical Exercise on Obesity in a Cohort of Southern Italian Obese Children: Improvement in Cardiovascular Risk and Immune System Biomarkers 84
Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference 84
Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): A meta-analysis 83
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" 82
Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy 82
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry 82
Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease 82
A pragmatic approach for thrombotic prevention after acute coronary syndromes 81
AZALEA–TIMI 71 trial: less bleeding with abelacimab compared to rivaroxaban in atrial fibrillation, but stroke prevention is uncertain 81
Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study 81
ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial 81
How has COVID-19 impacted the care of patients with acute coronary syndromes? 80
Left atrial and auricular thrombosis in patients with atrial fibrillation: from pathophysiology to treatment 80
Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol 79
Methicillin-resistant staphylococcus aureus: Risk for general infection and endocarditis among athletes 78
Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk 77
Exercise, immune system, nutrition, respiratory and cardiovascular diseases during COVID-19: A complex combination 77
Artificial intelligence in cardiovascular prevention: new ways will open new doors 76
Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia 75
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein? 75
Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve 75
Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention 74
Beyond the left ventricle: Why the right heart matters in Takotsubo syndrome 74
Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events 74
Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention 73
The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia 73
Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey 73
Reply to SGLT-2 inhibitors: Post-infarction interventional effects 72
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 71
Real-World Efficacy and Safety of Inclisiran: A Single-Country, Multicenter, Observational Study (CHOLINET Registry) 71
Laboratory medicine: health evaluation in elite athletes 71
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome 70
Epigenetic mechanisms underlying the beneficial effects of cardiac rehabilitation. An overview from the working groups of “cellular and molecular biology of the heart” and “cardiac rehabilitation and cardiovascular prevention” of the Italian Society of Cardiology (SIC) 69
Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease 69
Implementation of guideline‐directed medical therapy in patients with heart failure with reduced ejection fraction (OpTIMa‐HF Registry) 67
Geographic variations in percutaneous versus surgical coronary revascularization: A global perspective from the SYNTAXES trial 66
Lipid-lowering therapy in patients with coronary artery disease undergoing percutaneous coronary interventions in Italy: an expert opinion paper of Interventional Cardiology Working Group of Italian Society of Cardiology 66
Totale 9.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.273
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.273
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202193 0 0 0 0 0 0 34 2 11 7 30 9
2021/2022430 9 3 8 17 104 10 10 41 9 55 37 127
2022/2023863 84 56 19 59 77 46 2 57 428 5 14 16
2023/2024513 28 17 20 24 129 111 19 12 4 29 13 107
2024/20251.804 8 13 2 54 251 207 231 170 259 276 172 161
2025/20266.980 359 526 487 418 678 4.512 0 0 0 0 0 0
Totale 10.850